Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia

Expert Review of Clinical Immunology

Volumn 7, Issue 3, 2011, Pages 295-300

  Bello, Celeste ^a   Veliz, Marays ^a   Pinilla Ibarz, Javier ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

chronic lymphocytic leukemia; CLL; follicular lymphoma; NHL; non Hodgkin's lymphoma; ofatumumab

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GENMAB; LENALIDOMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; OFATUMUMAB; PENTOSTATIN; RITUXIMAB; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; FOLLICULAR LYMPHOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN;

EID: 79957500239     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.11.15     Document Type: Article

References (18)

1. Forstpointner R, Dreyling M, Repp R et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104, 3064-3071 (2004). (Pubitemid 39517009)
2. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105, 1417-1423 (2005). (Pubitemid 40223656)
3. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low- Grade Lymphoma Study Group. Blood 106, 3725-3732 (2005). (Pubitemid 41742196)
4. Hainsworth JD, Litchy S, Burris HA 3rd et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 20, 4261-4267 (2002). (Pubitemid 35191030)
5. Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 101, 949-954 (2004).
6. Teeling JL, Marcus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 J. Immunol. 177, 362-371 (2006). (Pubitemid 43939148)
7. Coiffier B, Lepretre S, Pedersen L et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a Phase 1-2 study. Blood 111, 1094-1100 (2008). (Pubitemid 351213387)
8. Wierda W, Kipps T, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1749-1755 (2010).
9. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19(8), 2153-2164 (2001). (Pubitemid 32366969)
10. O'Brien S, Kantarjian H, Cortes J et al. Rituximab dose escaltion trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 2165-2170 (2001). (Pubitemid 32366970)
11. Wierda W, Kipps T, Dürig J et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial. Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5-8 December 2009 (Abstract 207).
12. Keating M, O'Brien S, Lerner S et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL).Program and Abstracts of the 2004 ASCO Annual Meeting. New Orleans, LA, USA, 5-8 June 2004
13. Parikh S, Khattry N, Alai V et al. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).J. Clin. Oncol. 28(Suppl. 15S) (2010) (Abstract 6519).
14. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
15. Fischer K, Cramer P, Stilgenbauer S et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter Phase II trial of the German CLL study group (GCLLSG).Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5-8 December 2009 (Abstract 205).
16. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a Phase 1/2 trial. Blood 111, 5486-5495 (2008).
17. Hagenbeek A, Fayad L, Delwail V et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5-8 December 2009 (Abstract 935).
18. Rummel M, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany).Program and Abstracts of the 51st ASH Annual Meeting. New Orleans, LA, USA, 5-8 December 2009 (Abstract 405).